Cytovation

Cytovation company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers.

Company Details

Employees
12
Founded
-
Address
Solheimsgaten 11, Bergen,5058,norway
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Bergen
Looking for a particular Cytovation employee's phone or email?

Cytovation Questions

News

Cytovation Raises US$6m to Advance Phase 2 Development of - GlobeNewswire

Cytovation Raises US$6m to Advance Phase 2 Development of GlobeNewswire

Cytovation to Advance Development of CY-101 for Cancers - GlobeNewswire

Cytovation to Advance Development of CY-101 for Cancers GlobeNewswire

Cytovation secures $6m for trial of CY-101 to treat adrenocortical carcinoma - Clinical Trials Arena

Cytovation secures $6m for trial of CY-101 to treat adrenocortical carcinoma Clinical Trials Arena

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy - Yahoo Finance

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy Yahoo Finance

Cytovation melanoma study under way - Labiotech.eu

Cytovation melanoma study under way Labiotech.eu

Cytovation ASA bags additional US$6m to drive Phase II study - European Biotechnology Magazine

Cytovation ASA bags additional US$6m to drive Phase II study European Biotechnology Magazine

Norwegian deep tech startup brings its Series A to $28 million for clinical advancement of CyPep-1, a - ArcticStartup

Norwegian deep tech startup brings its Series A to $28 million for clinical advancement of CyPep-1, a ArcticStartup

Norwegian Biotech Put on the Map with €18M Oncology Round - Labiotech.eu

Norwegian Biotech Put on the Map with €18M Oncology Round Labiotech.eu

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells - Labiotech.eu

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells Labiotech.eu

Top Cytovation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant